Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients

Linsheng Guo, Mauricio Orrego, Hector Rodriguez-Luna, Vijiyan Balan, Thomas Byrne, Kapil Chopra, David D. Douglas, Edwyn Harrison, Adyr Moss, Kunam Sudhakar Reddy, James W. Williams, Jorge Rakela, David Mulligan, Hugo E Vargas

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The question of possible earlier and more aggressive recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation (LDLT) compared to deceased donor liver transplantation (DDLT) remains unanswered. To address this issue we retrospectively reviewed virological, histological, and clinical data in 67 patients (52 DDLT and 15 LDLT) who underwent liver transplant for their HCV-related cirrhosis since April 2001. Our data indicate that there is no statistical difference between LDLT and DDLT groups in mean age, Child-Turcotte-Pugh score, model for end-stage liver disease score, and gender distribution. The mean follow-up was 749 ± 371 days in LDLT and 692 ± 347 days in DDLT. The predominant genotype in the LDLT and DDLT are genotype 1 (LDLT, 91%; DDLT, 70%). All patients with histologically confirmed recurrent HCV had detectable HCV-RNA in serum. The histological recurrence rate of hepatitis C was 58% at 4 months, 90% at 1 year, and 100% at 2 years in LDLT patients vs. 71% at 4 months, 94% at 1 year, and 95% at 2 years in DDLT patients (not significant) Comparison of the activity of inflammation and fibrosis score at all time points failed to show a statistical difference. Kaplan-Meier survival analysis showed similar patient and graft survival rates between the 2 groups. Our data indicate that histological recurrence of HCV is an early event and virtually universal 2 years' posttransplantation, regardless of modality of donor procurement.

Original languageEnglish (US)
Pages (from-to)560-565
Number of pages6
JournalLiver Transplantation
Volume12
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Living Donors
Hepatitis C
Liver Transplantation
Fibrosis
Tissue Donors
Recurrence
Hepacivirus
Genotype
End Stage Liver Disease
Kaplan-Meier Estimate
Graft Survival
Virus Diseases
Survival Analysis

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Living donor liver transplantation for hepatitis C-related cirrhosis : No difference in histological recurrence when compared to deceased donor liver transplantation recipients. / Guo, Linsheng; Orrego, Mauricio; Rodriguez-Luna, Hector; Balan, Vijiyan; Byrne, Thomas; Chopra, Kapil; Douglas, David D.; Harrison, Edwyn; Moss, Adyr; Reddy, Kunam Sudhakar; Williams, James W.; Rakela, Jorge; Mulligan, David; Vargas, Hugo E.

In: Liver Transplantation, Vol. 12, No. 4, 04.2006, p. 560-565.

Research output: Contribution to journalArticle

Guo, Linsheng ; Orrego, Mauricio ; Rodriguez-Luna, Hector ; Balan, Vijiyan ; Byrne, Thomas ; Chopra, Kapil ; Douglas, David D. ; Harrison, Edwyn ; Moss, Adyr ; Reddy, Kunam Sudhakar ; Williams, James W. ; Rakela, Jorge ; Mulligan, David ; Vargas, Hugo E. / Living donor liver transplantation for hepatitis C-related cirrhosis : No difference in histological recurrence when compared to deceased donor liver transplantation recipients. In: Liver Transplantation. 2006 ; Vol. 12, No. 4. pp. 560-565.
@article{0b33011e86604cd2a1b8c6db61366f83,
title = "Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients",
abstract = "The question of possible earlier and more aggressive recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation (LDLT) compared to deceased donor liver transplantation (DDLT) remains unanswered. To address this issue we retrospectively reviewed virological, histological, and clinical data in 67 patients (52 DDLT and 15 LDLT) who underwent liver transplant for their HCV-related cirrhosis since April 2001. Our data indicate that there is no statistical difference between LDLT and DDLT groups in mean age, Child-Turcotte-Pugh score, model for end-stage liver disease score, and gender distribution. The mean follow-up was 749 ± 371 days in LDLT and 692 ± 347 days in DDLT. The predominant genotype in the LDLT and DDLT are genotype 1 (LDLT, 91{\%}; DDLT, 70{\%}). All patients with histologically confirmed recurrent HCV had detectable HCV-RNA in serum. The histological recurrence rate of hepatitis C was 58{\%} at 4 months, 90{\%} at 1 year, and 100{\%} at 2 years in LDLT patients vs. 71{\%} at 4 months, 94{\%} at 1 year, and 95{\%} at 2 years in DDLT patients (not significant) Comparison of the activity of inflammation and fibrosis score at all time points failed to show a statistical difference. Kaplan-Meier survival analysis showed similar patient and graft survival rates between the 2 groups. Our data indicate that histological recurrence of HCV is an early event and virtually universal 2 years' posttransplantation, regardless of modality of donor procurement.",
author = "Linsheng Guo and Mauricio Orrego and Hector Rodriguez-Luna and Vijiyan Balan and Thomas Byrne and Kapil Chopra and Douglas, {David D.} and Edwyn Harrison and Adyr Moss and Reddy, {Kunam Sudhakar} and Williams, {James W.} and Jorge Rakela and David Mulligan and Vargas, {Hugo E}",
year = "2006",
month = "4",
doi = "10.1002/lt.20660",
language = "English (US)",
volume = "12",
pages = "560--565",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Living donor liver transplantation for hepatitis C-related cirrhosis

T2 - No difference in histological recurrence when compared to deceased donor liver transplantation recipients

AU - Guo, Linsheng

AU - Orrego, Mauricio

AU - Rodriguez-Luna, Hector

AU - Balan, Vijiyan

AU - Byrne, Thomas

AU - Chopra, Kapil

AU - Douglas, David D.

AU - Harrison, Edwyn

AU - Moss, Adyr

AU - Reddy, Kunam Sudhakar

AU - Williams, James W.

AU - Rakela, Jorge

AU - Mulligan, David

AU - Vargas, Hugo E

PY - 2006/4

Y1 - 2006/4

N2 - The question of possible earlier and more aggressive recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation (LDLT) compared to deceased donor liver transplantation (DDLT) remains unanswered. To address this issue we retrospectively reviewed virological, histological, and clinical data in 67 patients (52 DDLT and 15 LDLT) who underwent liver transplant for their HCV-related cirrhosis since April 2001. Our data indicate that there is no statistical difference between LDLT and DDLT groups in mean age, Child-Turcotte-Pugh score, model for end-stage liver disease score, and gender distribution. The mean follow-up was 749 ± 371 days in LDLT and 692 ± 347 days in DDLT. The predominant genotype in the LDLT and DDLT are genotype 1 (LDLT, 91%; DDLT, 70%). All patients with histologically confirmed recurrent HCV had detectable HCV-RNA in serum. The histological recurrence rate of hepatitis C was 58% at 4 months, 90% at 1 year, and 100% at 2 years in LDLT patients vs. 71% at 4 months, 94% at 1 year, and 95% at 2 years in DDLT patients (not significant) Comparison of the activity of inflammation and fibrosis score at all time points failed to show a statistical difference. Kaplan-Meier survival analysis showed similar patient and graft survival rates between the 2 groups. Our data indicate that histological recurrence of HCV is an early event and virtually universal 2 years' posttransplantation, regardless of modality of donor procurement.

AB - The question of possible earlier and more aggressive recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation (LDLT) compared to deceased donor liver transplantation (DDLT) remains unanswered. To address this issue we retrospectively reviewed virological, histological, and clinical data in 67 patients (52 DDLT and 15 LDLT) who underwent liver transplant for their HCV-related cirrhosis since April 2001. Our data indicate that there is no statistical difference between LDLT and DDLT groups in mean age, Child-Turcotte-Pugh score, model for end-stage liver disease score, and gender distribution. The mean follow-up was 749 ± 371 days in LDLT and 692 ± 347 days in DDLT. The predominant genotype in the LDLT and DDLT are genotype 1 (LDLT, 91%; DDLT, 70%). All patients with histologically confirmed recurrent HCV had detectable HCV-RNA in serum. The histological recurrence rate of hepatitis C was 58% at 4 months, 90% at 1 year, and 100% at 2 years in LDLT patients vs. 71% at 4 months, 94% at 1 year, and 95% at 2 years in DDLT patients (not significant) Comparison of the activity of inflammation and fibrosis score at all time points failed to show a statistical difference. Kaplan-Meier survival analysis showed similar patient and graft survival rates between the 2 groups. Our data indicate that histological recurrence of HCV is an early event and virtually universal 2 years' posttransplantation, regardless of modality of donor procurement.

UR - http://www.scopus.com/inward/record.url?scp=33645552627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645552627&partnerID=8YFLogxK

U2 - 10.1002/lt.20660

DO - 10.1002/lt.20660

M3 - Article

C2 - 16555313

AN - SCOPUS:33645552627

VL - 12

SP - 560

EP - 565

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 4

ER -